A Bead‐Based Screening Platform for Identifying Monoclonal Antibodies That Disrupt PD‐1/PD‐L1 Interactions

Read full text Summarise with VIRAT
Authors: Veridiane Maria Pscheidt, Rodrigo Benedetti Gassen, José Tadeu Aranha Nunes, Deise Nascimento de Freitas, Valdir C. Barth, Fernanda Tereza Bovi Frozza, Milena D. Santos, Cláudia Paiva Nunes, Cristina Bonorino
Cited by: 0
References: 20

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Monoclonal antibodies (mAbs) targeting immune checkpoint pathways such as programmed cell death protein 1 (PD‐1)/PD‐L1 are central to modern immunotherapy, yet scalable methods to assess their functional blockade remain limited. We present a bead‐based flow cytometry assay for quantifying the inhibition of PD‐1/PD‐L1 interaction by antibodies. Recombinant human PD‐1 protein was conjugated to polystyrene beads, and its interaction with recombinant human PD‐L1 protein labeled with a fluorochrome was measured. The inhibitory activity of an anti‐PD‐L1 mAb was quantified based on their ability to disrupt this interaction. The assay was validated for intra‐ and inter‐assay precision, in addition, functionality was confirmed using a T cell coculture assay. The assay demonstrated dose‐dependent inhibition by the αPD‐L1 mAb, with a calculated mean IC 50 of 3.122 µg/mL. The method proved to be reproducible for the determination of antibody blocking activity, with relative standard deviation (RSD) < 20% between three independent runs. At the concentration approximating the IC 50 detected on the bead assay, the antibody significantly restored CD69 expression on the T cell surface ( p = 0.0001) in a coculture in vitro system. In addition, the methodology could successfully distinguish the blocking capacity of two anti‐PD‐L1 antibodies with different affinities. This high‐throughput compatible platform offers a reliable tool for screening PD‐1/PD‐L1 blocking antibodies, supporting immunotherapy discovery and development.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Monoclonal and Polyclonal Antibodies Research T-cell and B-cell Immunology

Publication details

Journal / source
Journal of Immunology Research
Volume
2026
Issue
1
Pages
e5189659–e5189659
Publication date
1 January 2026
Language
EN